Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Bristol Myers Squibb's Growth Portfolio Just Hit $7.7 Billion. Is This Cheap Pharma Stock a No-Brainer Buy?

The good news is that Bristol Myers Squibb's new drugs are growing; the bad news is that one old drug is nearing its patent expiration.

Bristol Myers Squibb (BMY) has recently reported a significant boost in its "growth portfolio" revenue, reaching nearly $7.7 billion in a single quarter. This represents a 12% increase compared to the same period in 2025. However, the question remains: is this pharmaceutical giant's stock a wise investment? Despite the success of its growth portfolio, investors are generally pessimistic about the stock. To understand why, let's delve into the details.

The company's growth portfolio comprises over a dozen new drugs, which make up nearly 60% of its drug revenues as of Q3. This is a positive sign, but it's also a double-edged sword. The legacy portfolio of Bristol Myers Squibb, which includes long-standing drugs, accounts for the remaining 40% of revenues. A key player in this legacy portfolio is Eliquis, a drug set to face generic competition by 2028.

This impending competition could significantly impact the revenue generated by this drug, potentially causing a sharp decline.

The company's dividend yield stands at an attractive 4.3%, significantly higher than the S&P 500's 1.1%, the average healthcare stock's 1.3%, and the average drug stock's 1.3%. Additionally, the company's high dividend payout ratio of around 55% leaves ample room for adversity, which should appease most investors. Furthermore, the dividend has been consistently increased for over three decades, with no cuts despite difficult periods.

The stock's price-to-earnings ratio is notably lower than the industry average of around 28x, which may appeal to value investors. However, the success of the growth portfolio is tempered by the fact that the company's legacy portfolio still contributes to a significant portion of the total revenues. The uncertainty around Eliquis' patent expiration and potential revenue drop looms large.

Despite these concerns, the company's track record suggests it will navigate through these challenges. The growth portfolio's success indicates Bristol Myers Squibb's continued prowess in new drug development. However, potential investors must be prepared to handle the uncertainty surrounding Eliquis' patent expiration. For most investors, including those interested in dividends, value, and growth, Bristol Myers Squibb appears to be worth a closer look.

The market seems to undervalue the company's recent successes, which could tilt the risk-reward balance in its favor. If you're considering investing in Bristol Myers Squibb, it's worth conducting a thorough analysis.

Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Also reported by 1 other outlet

Every outlet that reported this, and when →

Read the original at fool.com →